Stem definition | Drug id | CAS RN |
---|---|---|
spasmolytics with a papaverine-like action | 2028 | 5633-20-5 |
Dose | Unit | Route |
---|---|---|
15 | mg | O |
3.90 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.80 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.93 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 6 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.85 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 7.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 16, 1975 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Multiple sclerosis relapse | 222.46 | 10.28 | 219 | 37652 | 41906 | 46606285 |
Urinary tract infection | 205.04 | 10.28 | 510 | 37361 | 219756 | 46428435 |
Fall | 186.65 | 10.28 | 638 | 37233 | 328459 | 46319732 |
Multiple sclerosis | 118.19 | 10.28 | 122 | 37749 | 24669 | 46623522 |
Urinary incontinence | 110.80 | 10.28 | 126 | 37745 | 28404 | 46619787 |
Application site erythema | 93.47 | 10.28 | 55 | 37816 | 4849 | 46643342 |
Dry mouth | 89.28 | 10.28 | 160 | 37711 | 54766 | 46593425 |
Urine analysis abnormal | 64.51 | 10.28 | 41 | 37830 | 4149 | 46644042 |
Gait disturbance | 63.87 | 10.28 | 260 | 37611 | 145003 | 46503188 |
Rheumatoid arthritis | 54.44 | 10.28 | 69 | 37802 | 240146 | 46408045 |
Balance disorder | 52.17 | 10.28 | 142 | 37729 | 64379 | 46583812 |
Exposure during pregnancy | 50.03 | 10.28 | 13 | 37858 | 108199 | 46539992 |
Micturition urgency | 49.54 | 10.28 | 45 | 37826 | 7772 | 46640419 |
Laboratory test abnormal | 47.03 | 10.28 | 74 | 37797 | 22773 | 46625418 |
Application site pruritus | 46.70 | 10.28 | 33 | 37838 | 3980 | 46644211 |
Maternal exposure during pregnancy | 44.30 | 10.28 | 14 | 37857 | 102535 | 46545656 |
Neurogenic bladder | 41.17 | 10.28 | 27 | 37844 | 2883 | 46645308 |
Secondary progressive multiple sclerosis | 41.12 | 10.28 | 20 | 37851 | 1200 | 46646991 |
Bladder disorder | 39.57 | 10.28 | 38 | 37833 | 7040 | 46641151 |
Pollakiuria | 38.54 | 10.28 | 70 | 37801 | 24191 | 46624000 |
Hypertonic bladder | 38.00 | 10.28 | 26 | 37845 | 2978 | 46645213 |
Product adhesion issue | 36.36 | 10.28 | 31 | 37840 | 4924 | 46643267 |
Systemic lupus erythematosus | 33.85 | 10.28 | 6 | 37865 | 65174 | 46583017 |
Urine leukocyte esterase positive | 32.20 | 10.28 | 22 | 37849 | 2513 | 46645678 |
Culture urine positive | 30.75 | 10.28 | 24 | 37847 | 3367 | 46644824 |
Joint swelling | 30.53 | 10.28 | 55 | 37816 | 166018 | 46482173 |
Muscular weakness | 30.25 | 10.28 | 151 | 37720 | 91693 | 46556498 |
Mental status changes | 29.95 | 10.28 | 83 | 37788 | 38005 | 46610186 |
Incontinence | 29.22 | 10.28 | 38 | 37833 | 9824 | 46638367 |
White blood cells urine positive | 28.76 | 10.28 | 25 | 37846 | 4075 | 46644116 |
Confusional state | 28.22 | 10.28 | 224 | 37647 | 159668 | 46488523 |
Escherichia urinary tract infection | 27.86 | 10.28 | 38 | 37833 | 10285 | 46637906 |
Malignant neoplasm progression | 27.79 | 10.28 | 9 | 37862 | 64917 | 46583274 |
Band neutrophil percentage increased | 26.88 | 10.28 | 9 | 37862 | 201 | 46647990 |
Dysuria | 26.33 | 10.28 | 65 | 37806 | 27768 | 46620423 |
Monocyte percentage increased | 26.14 | 10.28 | 14 | 37857 | 1029 | 46647162 |
Febrile neutropenia | 26.08 | 10.28 | 23 | 37848 | 94604 | 46553587 |
Gait inability | 25.05 | 10.28 | 74 | 37797 | 35129 | 46613062 |
Off label use | 25.01 | 10.28 | 193 | 37678 | 379648 | 46268543 |
Application site rash | 25.00 | 10.28 | 19 | 37852 | 2563 | 46645628 |
Myelocyte percentage increased | 24.53 | 10.28 | 8 | 37863 | 164 | 46648027 |
Cerebral atrophy | 23.90 | 10.28 | 24 | 37847 | 4692 | 46643499 |
Bacterial test | 23.84 | 10.28 | 14 | 37857 | 1229 | 46646962 |
Urinary sediment present | 23.61 | 10.28 | 16 | 37855 | 1804 | 46646387 |
Synovitis | 23.56 | 10.28 | 10 | 37861 | 61065 | 46587126 |
Muscle spasticity | 23.46 | 10.28 | 37 | 37834 | 11403 | 46636788 |
Urine oxalate increased | 23.27 | 10.28 | 8 | 37863 | 194 | 46647997 |
Abortion spontaneous | 22.70 | 10.28 | 4 | 37867 | 43642 | 46604549 |
Red blood cells urine positive | 22.66 | 10.28 | 18 | 37853 | 2589 | 46645602 |
Band neutrophil count increased | 22.59 | 10.28 | 9 | 37862 | 333 | 46647858 |
Prescription drug used without a prescription | 22.29 | 10.28 | 14 | 37857 | 1388 | 46646803 |
Cystitis | 22.13 | 10.28 | 80 | 37791 | 42161 | 46606030 |
Bladder spasm | 21.60 | 10.28 | 14 | 37857 | 1465 | 46646726 |
Hallucination | 21.58 | 10.28 | 89 | 37782 | 49862 | 46598329 |
Dysmetropsia | 21.15 | 10.28 | 6 | 37865 | 75 | 46648116 |
Crystal urine present | 21.09 | 10.28 | 13 | 37858 | 1246 | 46646945 |
Injection site scar | 21.05 | 10.28 | 11 | 37860 | 769 | 46647422 |
Treatment failure | 20.77 | 10.28 | 27 | 37844 | 93060 | 46555131 |
Urinary retention | 20.69 | 10.28 | 57 | 37814 | 26004 | 46622187 |
Retinal depigmentation | 20.67 | 10.28 | 8 | 37863 | 274 | 46647917 |
Hallucination, visual | 20.48 | 10.28 | 45 | 37826 | 17828 | 46630363 |
Food refusal | 20.42 | 10.28 | 8 | 37863 | 283 | 46647908 |
Specific gravity urine decreased | 20.31 | 10.28 | 9 | 37862 | 436 | 46647755 |
Neutropenia | 20.09 | 10.28 | 55 | 37816 | 143149 | 46505042 |
Asthenia | 20.06 | 10.28 | 359 | 37512 | 310716 | 46337475 |
Lymphocyte percentage decreased | 20.04 | 10.28 | 17 | 37854 | 2682 | 46645509 |
Depression | 19.77 | 10.28 | 218 | 37653 | 169886 | 46478305 |
Psychotic symptom | 19.46 | 10.28 | 11 | 37860 | 899 | 46647292 |
Toxicity to various agents | 19.42 | 10.28 | 97 | 37774 | 211669 | 46436522 |
Urinary tract infection bacterial | 18.95 | 10.28 | 20 | 37851 | 4145 | 46644046 |
Myelocyte count increased | 18.80 | 10.28 | 8 | 37863 | 351 | 46647840 |
Dementia | 18.73 | 10.28 | 39 | 37832 | 14891 | 46633300 |
Amnesia | 18.64 | 10.28 | 75 | 37796 | 41556 | 46606635 |
Lymphocyte count decreased | 18.40 | 10.28 | 54 | 37817 | 25535 | 46622656 |
Thrombocytopenia | 18.22 | 10.28 | 48 | 37823 | 126533 | 46521658 |
Drug intolerance | 18.10 | 10.28 | 60 | 37811 | 146989 | 46501202 |
Hepatic enzyme increased | 17.97 | 10.28 | 24 | 37847 | 81763 | 46566428 |
Chronic papillomatous dermatitis | 17.81 | 10.28 | 5 | 37866 | 60 | 46648131 |
Head injury | 17.73 | 10.28 | 52 | 37819 | 24584 | 46623607 |
Product administered at inappropriate site | 17.67 | 10.28 | 15 | 37856 | 2368 | 46645823 |
Nocturia | 17.38 | 10.28 | 25 | 37846 | 7107 | 46641084 |
Application site vesicles | 16.95 | 10.28 | 12 | 37859 | 1452 | 46646739 |
Lagophthalmos | 16.87 | 10.28 | 7 | 37864 | 288 | 46647903 |
Drug abuse | 16.77 | 10.28 | 16 | 37855 | 63392 | 46584799 |
Application site irritation | 16.76 | 10.28 | 13 | 37858 | 1806 | 46646385 |
Dermatitis contact | 16.28 | 10.28 | 26 | 37845 | 8097 | 46640094 |
Injection related reaction | 15.99 | 10.28 | 8 | 37863 | 510 | 46647681 |
Glossodynia | 15.97 | 10.28 | 8 | 37863 | 44365 | 46603826 |
Lymphopenia | 15.85 | 10.28 | 37 | 37834 | 15256 | 46632935 |
Abdominal discomfort | 15.78 | 10.28 | 66 | 37805 | 151099 | 46497092 |
Urine abnormality | 15.72 | 10.28 | 21 | 37850 | 5573 | 46642618 |
Infusion related reaction | 15.64 | 10.28 | 37 | 37834 | 101171 | 46547020 |
Porphyria acute | 15.13 | 10.28 | 7 | 37864 | 375 | 46647816 |
Urinary tract infection pseudomonal | 14.78 | 10.28 | 9 | 37862 | 844 | 46647347 |
Anaphylactic reaction | 14.52 | 10.28 | 13 | 37858 | 53099 | 46595092 |
Urine odour abnormal | 14.51 | 10.28 | 19 | 37852 | 4943 | 46643248 |
Thyroglobulin increased | 14.49 | 10.28 | 4 | 37867 | 45 | 46648146 |
Neutrophil percentage increased | 14.22 | 10.28 | 14 | 37857 | 2673 | 46645518 |
Skin irritation | 14.16 | 10.28 | 23 | 37848 | 7264 | 46640927 |
Resting tremor | 13.95 | 10.28 | 8 | 37863 | 672 | 46647519 |
Decubitus ulcer | 13.78 | 10.28 | 27 | 37844 | 9871 | 46638320 |
Pyelonephritis | 13.62 | 10.28 | 35 | 37836 | 15322 | 46632869 |
Product complaint | 13.34 | 10.28 | 30 | 37841 | 12071 | 46636120 |
Dizziness | 13.08 | 10.28 | 365 | 37506 | 340049 | 46308142 |
Stress urinary incontinence | 13.05 | 10.28 | 12 | 37859 | 2104 | 46646087 |
Pregnancy | 13.04 | 10.28 | 3 | 37868 | 27134 | 46621057 |
Arthralgia | 12.93 | 10.28 | 213 | 37658 | 364390 | 46283801 |
Bone marrow failure | 12.89 | 10.28 | 4 | 37867 | 29665 | 46618526 |
Impaired self-care | 12.85 | 10.28 | 11 | 37860 | 1757 | 46646434 |
Open fracture | 12.84 | 10.28 | 6 | 37865 | 329 | 46647862 |
Hepatic function abnormal | 12.70 | 10.28 | 6 | 37865 | 34415 | 46613776 |
Repetitive strain injury | 12.60 | 10.28 | 5 | 37866 | 183 | 46648008 |
Product closure removal difficult | 12.53 | 10.28 | 3 | 37868 | 18 | 46648173 |
Intentional overdose | 12.38 | 10.28 | 21 | 37850 | 64923 | 46583268 |
Memory impairment | 12.36 | 10.28 | 106 | 37765 | 77231 | 46570960 |
Prescribed underdose | 12.31 | 10.28 | 29 | 37842 | 12024 | 46636167 |
Nephrolithiasis | 12.07 | 10.28 | 56 | 37815 | 32995 | 46615196 |
Drug withdrawal syndrome neonatal | 12.02 | 10.28 | 11 | 37860 | 1917 | 46646274 |
Walking aid user | 11.95 | 10.28 | 17 | 37854 | 4783 | 46643408 |
Nausea | 11.95 | 10.28 | 447 | 37424 | 687007 | 45961184 |
Body height decreased | 11.86 | 10.28 | 25 | 37846 | 9627 | 46638564 |
Mixed incontinence | 11.75 | 10.28 | 4 | 37867 | 94 | 46648097 |
Interstitial lung disease | 11.67 | 10.28 | 16 | 37855 | 53933 | 46594258 |
Incision site pruritus | 11.67 | 10.28 | 3 | 37868 | 25 | 46648166 |
Hallucinations, mixed | 11.67 | 10.28 | 15 | 37856 | 3834 | 46644357 |
Vertigo | 11.51 | 10.28 | 77 | 37794 | 51971 | 46596220 |
Haemoglobin urine present | 11.47 | 10.28 | 7 | 37864 | 659 | 46647532 |
Intestinal pseudo-obstruction | 11.46 | 10.28 | 7 | 37864 | 660 | 46647531 |
Basophil count decreased | 11.34 | 10.28 | 4 | 37867 | 105 | 46648086 |
Dysarthria | 11.19 | 10.28 | 60 | 37811 | 37438 | 46610753 |
Klebsiella test positive | 11.14 | 10.28 | 8 | 37863 | 989 | 46647202 |
Anaemia folate deficiency | 11.13 | 10.28 | 5 | 37866 | 250 | 46647941 |
Tri-iodothyronine increased | 11.03 | 10.28 | 4 | 37867 | 114 | 46648077 |
Coordination abnormal | 10.81 | 10.28 | 26 | 37845 | 10923 | 46637268 |
Urinary tract disorder | 10.54 | 10.28 | 11 | 37860 | 2249 | 46645942 |
Visual impairment | 10.44 | 10.28 | 91 | 37780 | 66598 | 46581593 |
Incision site erythema | 10.42 | 10.28 | 5 | 37866 | 291 | 46647900 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 150.68 | 13.02 | 175 | 13246 | 73484 | 29865573 |
Dry mouth | 82.76 | 13.02 | 74 | 13347 | 22776 | 29916281 |
Fall | 69.95 | 13.02 | 209 | 13212 | 181663 | 29757394 |
Multiple sclerosis relapse | 64.51 | 13.02 | 47 | 13374 | 10815 | 29928242 |
Confusional state | 63.64 | 13.02 | 167 | 13254 | 134667 | 29804390 |
Multiple sclerosis | 46.72 | 13.02 | 33 | 13388 | 7234 | 29931823 |
Muscle spasticity | 41.56 | 13.02 | 27 | 13394 | 5161 | 29933896 |
Disorganised speech | 34.90 | 13.02 | 12 | 13409 | 537 | 29938520 |
Urinary retention | 30.89 | 13.02 | 54 | 13367 | 32863 | 29906194 |
Bladder spasm | 26.04 | 13.02 | 11 | 13410 | 867 | 29938190 |
Daydreaming | 25.01 | 13.02 | 9 | 13412 | 461 | 29938596 |
Constipation | 24.62 | 13.02 | 108 | 13313 | 112798 | 29826259 |
Completed suicide | 23.09 | 13.02 | 97 | 13324 | 99395 | 29839662 |
Hallucination | 21.28 | 13.02 | 59 | 13362 | 49000 | 29890057 |
Urosepsis | 21.04 | 13.02 | 25 | 13396 | 10707 | 29928350 |
Syncope | 19.87 | 13.02 | 83 | 13338 | 84820 | 29854237 |
Urinary incontinence | 18.84 | 13.02 | 30 | 13391 | 16910 | 29922147 |
Delirium | 18.76 | 13.02 | 50 | 13371 | 40581 | 29898476 |
Nephrolithiasis | 18.63 | 13.02 | 37 | 13384 | 24773 | 29914284 |
Pollakiuria | 17.52 | 13.02 | 29 | 13392 | 16877 | 29922180 |
Gait disturbance | 17.41 | 13.02 | 73 | 13348 | 74704 | 29864353 |
Interstitial lung disease | 17.41 | 13.02 | 3 | 13418 | 60194 | 29878863 |
Intestinal pseudo-obstruction | 17.29 | 13.02 | 9 | 13412 | 1137 | 29937920 |
Dizziness | 17.01 | 13.02 | 147 | 13274 | 194762 | 29744295 |
Neurogenic bladder | 16.85 | 13.02 | 10 | 13411 | 1629 | 29937428 |
Decubitus ulcer | 16.70 | 13.02 | 19 | 13402 | 7769 | 29931288 |
Granulocytopenia | 16.52 | 13.02 | 17 | 13404 | 6209 | 29932848 |
Cognitive disorder | 16.22 | 13.02 | 34 | 13387 | 23656 | 29915401 |
Rib hypoplasia | 15.31 | 13.02 | 3 | 13418 | 12 | 29939045 |
Pulmonary hypoplasia | 14.81 | 13.02 | 6 | 13415 | 425 | 29938632 |
Amnesia | 14.48 | 13.02 | 33 | 13388 | 24288 | 29914769 |
Vision blurred | 14.08 | 13.02 | 46 | 13375 | 41770 | 29897287 |
Implant site erosion | 14.05 | 13.02 | 4 | 13417 | 95 | 29938962 |
Muscular weakness | 13.94 | 13.02 | 61 | 13360 | 63584 | 29875473 |
Haematuria | 13.93 | 13.02 | 48 | 13373 | 44786 | 29894271 |
Tongue haemorrhage | 13.92 | 13.02 | 6 | 13415 | 497 | 29938560 |
Mental status changes | 13.59 | 13.02 | 42 | 13379 | 37037 | 29902020 |
Hypertonic bladder | 13.54 | 13.02 | 7 | 13414 | 872 | 29938185 |
Asthenia | 13.52 | 13.02 | 155 | 13266 | 221135 | 29717922 |
Abnormal behaviour | 13.34 | 13.02 | 33 | 13388 | 25590 | 29913467 |
Hepatitis acute | 13.06 | 13.02 | 16 | 13405 | 7067 | 29931990 |
Bladder catheterisation | 13.06 | 13.02 | 6 | 13415 | 578 | 29938479 |
Source | Code | Description |
---|---|---|
ATC | G04BD04 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
FDA MoA | N0000000125 | Cholinergic Muscarinic Antagonists |
FDA EPC | N0000175700 | Cholinergic Muscarinic Antagonist |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D010276 | Parasympatholytics |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D064804 | Urological Agents |
CHEBI has role | CHEBI:36333 | local anesthetics |
CHEBI has role | CHEBI:38215 | calcium channel blockers |
CHEBI has role | CHEBI:48876 | antimuskarinika |
CHEBI has role | CHEBI:50370 | parasympatholytics |
CHEBI has role | CHEBI:51371 | muscle relaxants |
CHEBI has role | CHEBI:53784 | antispasmodics |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Urgent desire to urinate | indication | 75088002 | |
Urge incontinence of urine | indication | 87557004 | |
Bladder muscle dysfunction - overactive | indication | 236633002 | |
Neurogenic bladder | indication | 398064005 | |
Increased Urinary Frequency | indication | ||
Sinus tachycardia | contraindication | 11092001 | |
Severe chronic ulcerative colitis | contraindication | 14311001 | |
Toxic megacolon | contraindication | 28536002 | DOID:1770 |
Atony of colon | contraindication | 29479008 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Paralytic ileus | contraindication | 55525008 | DOID:8442 |
Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
Hiatal hernia | contraindication | 84089009 | DOID:12642 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Gastrointestinal obstruction | contraindication | 126765001 | |
Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Benign prostatic hyperplasia | contraindication | 266569009 | |
Retention of urine | contraindication | 267064002 | |
Drowsy | contraindication | 271782001 | |
Gastric retention | contraindication | 307227006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Disorder of coronary artery | contraindication | 414024009 | |
Gastrointestinal hypomotility | contraindication | 421807004 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.67 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M1 | GPCR | ANTAGONIST | Ki | 9 | CHEMBL | DRUG LABEL | |||
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | Ki | 9.11 | CHEMBL | DRUG LABEL | |||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.30 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.84 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 7.17 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 6.22 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | Ki | 8.09 | CHEMBL | ||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.44 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.99 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.85 | CHEMBL | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.59 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.09 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.23 | CHEMBL | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 9.02 | CHEMBL | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.16 | CHEMBL |
ID | Source |
---|---|
4018815 | VUID |
N0000147118 | NUI |
D00465 | KEGG_DRUG |
1508-65-2 | SECONDARY_CAS_RN |
4018815 | VANDF |
4019869 | VANDF |
C0591395 | UMLSCUI |
CHEBI:7856 | CHEBI |
CHEMBL1133 | ChEMBL_ID |
CHEMBL1231 | ChEMBL_ID |
DB01062 | DRUGBANK_ID |
C005419 | MESH_SUPPLEMENTAL_RECORD_UI |
4634 | PUBCHEM_CID |
359 | IUPHAR_LIGAND_ID |
1354 | INN_ID |
K9P6MC7092 | UNII |
151651 | RXNORM |
180 | MMSL |
28244 | MMSL |
4610 | MMSL |
46359 | MMSL |
5214 | MMSL |
d00328 | MMSL |
001768 | NDDF |
004715 | NDDF |
31815007 | SNOMEDCT_US |
35768004 | SNOMEDCT_US |
372717000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5812 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
GELNIQUE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-5861 | GEL | 100 mg | TRANSDERMAL | NDA | 27 sections |
OXYTROL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0023-6153 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 26 sections |
Oxytrol for Women | HUMAN OTC DRUG LABEL | 1 | 0023-9637 | PATCH | 3.90 mg | TRANSDERMAL | NDA | 14 sections |
OXYBUTYNIN CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0671 | SYRUP | 5 mg | ORAL | ANDA | 18 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0603-4975 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-3512 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-7521 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | NDA | 23 sections |
oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8219 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8220 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-0038 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-2821 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6570 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 25 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-609 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-610 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-611 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 29 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-640 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-518 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-559 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-201 | TABLET | 5 mg | ORAL | ANDA | 22 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14539-653 | TABLET | 5 mg | ORAL | ANDA | 13 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-317 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 26 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-318 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 26 sections |
oxybutynin chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-319 | TABLET, EXTENDED RELEASE | 15 mg | ORAL | ANDA | 26 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0092 | SYRUP | 5 mg | ORAL | ANDA | 17 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-0149 | SYRUP | 5 mg | ORAL | ANDA | 21 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17856-1491 | SOLUTION | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-406 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Oxybutynin Chloride | Human Prescription Drug Label | 1 | 27241-155 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | ANDA | 25 sections |
Oxybutynin Chloride | Human Prescription Drug Label | 1 | 27241-156 | TABLET, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 25 sections |